Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Asian Pac J Cancer Prev ; 16(9): 3805-10, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-25987041

RESUMO

Arsenic trioxide (ATO) has been found to exert anti-cancer activity in various human malignancies. However, the molecular mechanisms by which ATO inhibits tumorigenesis are not fully elucidated. In the current study, we explored the molecular basis of ATO-mediated tumor growth inhibition in pancreatic cancer cells. We used multiple approaches such as MTT assay, wound healing assay, Transwell invasion assay, annexin V-FITC, cell cycle analysis, RT-PCR and Western blotting to achieve our goal. We found that ATO treatment effectively caused cell growth inhibition, suppressed clonogenic potential and induced G2-M cell cycle arrest and apoptosis in pancreatic cancer cells. Moreover, we observed a significant down-regulation of Skp2 after treatment with ATO. Furthermore, we revealed that ATO regulated Skp2 downstream genes such as FOXO1 and p53. These findings demonstrate that inhibition of Skp2 could be a novel strategy for the treatment of pancreatic cancer by ATO.


Assuntos
Antineoplásicos/farmacologia , Arsenicais/farmacologia , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Óxidos/farmacologia , Neoplasias Pancreáticas/patologia , Proteínas Quinases Associadas a Fase S/metabolismo , Apoptose/efeitos dos fármacos , Trióxido de Arsênio , Western Blotting , Ciclo Celular/efeitos dos fármacos , Citometria de Fluxo , Humanos , Neoplasias Pancreáticas/tratamento farmacológico , Neoplasias Pancreáticas/metabolismo , Transdução de Sinais , Células Tumorais Cultivadas , Cicatrização/efeitos dos fármacos
2.
Inorg Chem ; 48(14): 6341-3, 2009 Jul 20.
Artigo em Inglês | MEDLINE | ID: mdl-19552381

RESUMO

Single-crystal-to-single-crystal transformation of one-dimensional 4d-4f coordination polymers has been investigated for the first time. More importantly, we observed the transformation of a meso-helical chain to a rac-helical chain as a function of the temperature.

3.
Acta Crystallogr Sect E Struct Rep Online ; 64(Pt 2): m328-9, 2008 Jan 09.
Artigo em Inglês | MEDLINE | ID: mdl-21201296

RESUMO

In the title compound, [Zn(C(8)H(8)N(3)S(2))(2)], the Zn atom is coordinated by the two ligands in a tridentate manner, via the pyridyl N, the azomethine N and the thiol-ate S atom; the coordination geometry is distorted octa-hedral, with the two ligands in the mer configuration (two S atoms and two pyridyl N atoms are cis with respect to each other and the azomethine N atoms is trans). The mol-ecules are linked by C-H⋯S hydrogen bonds, forming a three-dimensional network structure.

4.
Zhongguo Zhong Xi Yi Jie He Za Zhi ; 24(2): 136-9, 2004 Feb.
Artigo em Chinês | MEDLINE | ID: mdl-15015448

RESUMO

OBJECTIVE: To explore the effect of Yiqi Huoxue recipe (YHR), a Chinese herbal medicine for supplementing Qi, activating blood circulation to remove stasis, on vascular extracellular matrix (ECM) remodeling and its molecular mechanism. METHODS: Vascular smooth muscle cell (VSMC) proliferation activity and collagen turnover rate were detected by 3H-TdR test and hydroxyproline amount determined by 3H-Pro incorporation. Expression activity of MMP-2 and osteopontin genes was detected by Northern blotting and MMP-2 zymography analysis. RESULTS: YHR could markedly inhibit VSMC collagen synthesis stimulated by blasic fibroblast growth factor (bFGF) and lower the collagen turnover rate induced by vascular de-endothelialization. The expression level of MMP-2 and osteopontin genes was down-regulated by YHR in cultured VSMC and vascular wall with endothelial injury, and VSMC proliferation was inhibited by the serum obtained from YHR treated rats. Removing protein from the drug serum made no change on the effect of YHR to VSMC. CONCLUSION: YHR could inhibit and/or retard ECM remodeling through regulating the expression of MMP-2 and osteopontin genes and lowering the collagen turnover rate.


Assuntos
Colágeno/metabolismo , Medicamentos de Ervas Chinesas/farmacologia , Metaloproteinase 2 da Matriz/metabolismo , Músculo Liso Vascular/metabolismo , Sialoglicoproteínas/metabolismo , Animais , Aorta/citologia , Divisão Celular/efeitos dos fármacos , Células Cultivadas , Colágeno/genética , Matriz Extracelular/genética , Matriz Extracelular/metabolismo , Fator 2 de Crescimento de Fibroblastos/metabolismo , Expressão Gênica , Masculino , Metaloproteinase 2 da Matriz/genética , Músculo Liso Vascular/citologia , Osteopontina , Ratos , Ratos Sprague-Dawley , Sialoglicoproteínas/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...